Literature DB >> 280739

Trends and variability in survival from osteosarcoma.

W F Taylor, J C Ivins, D C Dahlin, J H Edmonson, D J Pritchard.   

Abstract

Survival of patients with primary osteosarcoma who received traditional surgical management has been very poor. Several studies have reported the percentage of patients alive 3 years after first treatment to be between 20 and 25%. In a study of such patients first treated at the Mayo Clinic between Jan. 1, 1963, and July 1, 1974, the survival noted in the first few years was typical of that of other reports, about 25%. However, by 1972 through mid-1974, the 3-year survival had become 50%. This improvement was not the result of adjuvant treatment or any basic change in type of patient treated, yet it is similar to that reported in connection with some of the new adjuvant therapies used in trials depending on historical controls. Our results cast doubt on findings made in the absence of concurrent, randomly selected controls.

Entities:  

Mesh:

Year:  1978        PMID: 280739

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  20 in total

1.  Orthopedics-epitomes of progress: sarcoma of bone: current management.

Authors:  E G Bovill
Journal:  West J Med       Date:  1980-11

Review 2.  Current impact of adjuvant chemotherapy in resectable cancer.

Authors:  A Rossi; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 3.  [Bone and soft tissue tumors--general strategy of therapy].

Authors:  H P Bruch
Journal:  Langenbecks Arch Chir       Date:  1987

4.  [Pre- and postoperative chemotherapy in bone and soft tissue tumors].

Authors:  K Höffken
Journal:  Langenbecks Arch Chir       Date:  1987

5.  Case report 425: Chondroblastic osteosarcoma: clear-cell variant of femur.

Authors:  A K Raymond; G F Murphy; D I Rosenthal
Journal:  Skeletal Radiol       Date:  1987       Impact factor: 2.199

6.  Limb-salvage procedures for osteosarcoma. An alternative to amputation.

Authors:  A C Wong; Y Akahoshi; S Takeuchi
Journal:  Int Orthop       Date:  1986       Impact factor: 3.075

7.  Correlation between lymphocyte-mediated auto-tumor reactivities and clinical course. I. Evaluation of 46 patients with sarcoma.

Authors:  F Vánky; J Willems; A Kreicbergs; T Aparisi; M Andréen; L A Broström; U Nilsonne; E Klein; G Klein
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma.

Authors:  Seong-Hwan Moon; Kyoo-Ho Shin; Jin-Suck Suh; Woo-Ick Yang; Jae-Keong Noh; Soo-Bong Hahn
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

9.  Osteosarcoma of the pelvis: outcome analysis of surgical treatment.

Authors:  Bruno Fuchs; Nathan Hoekzema; Dirk R Larson; Carrie Y Inwards; Franklin H Sim
Journal:  Clin Orthop Relat Res       Date:  2008-10-15       Impact factor: 4.176

10.  [Multidrug chemotherapy of osteogenic sarcoma (author's transl)].

Authors:  G Prindull
Journal:  Blut       Date:  1979-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.